Evidence map›Paper›PMID 37093434›Full record

ArticleAdvances in experimental medicine and biology2023

The "Ins and Outs" of Prostate Specific Membrane Antigen (PSMA) as Specific Target in Prostate Cancer Therapy.

Felipe Eltit, Nicole Robinson, Pak Lok Ivan Yu, Mitali Pandey, Jerome Lozada, Yubin Guo, Manju Sharma, Dogancan Ozturan, Laetitia Ganier, Eric Belanger and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Advances in experimental medicine and biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
9.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 2 countries.

Felipe EltitDepartment of Urologic Sciences, University of British Columbia, 2775 Laurel Street, Vancouver, BC, V5Z 1M9, Canada.
Nicole RobinsonDepartment of Urologic Sciences, University of British Columbia, 2775 Laurel Street, Vancouver, BC, V5Z 1M9, Canada.
Pak Lok Ivan YuDepartment of Urologic Sciences, University of British Columbia, 2775 Laurel Street, Vancouver, BC, V5Z 1M9, Canada.
Mitali PandeyDepartment of Urologic Sciences, University of British Columbia, 2775 Laurel Street, Vancouver, BC, V5Z 1M9, Canada.
Jerome LozadaDepartment of Chemistry, University of British Columbia, Vancouver, BC, Canada.
Yubin GuoDepartment of Urologic Sciences, University of British Columbia, 2775 Laurel Street, Vancouver, BC, V5Z 1M9, Canada.
Manju SharmaDepartment of Urologic Sciences, University of British Columbia, 2775 Laurel Street, Vancouver, BC, V5Z 1M9, Canada.
Dogancan OzturanDepartment of Urologic Sciences, University of British Columbia, 2775 Laurel Street, Vancouver, BC, V5Z 1M9, Canada.
Laetitia GanierDepartment of Urologic Sciences, University of British Columbia, 2775 Laurel Street, Vancouver, BC, V5Z 1M9, Canada.
Eric BelangerDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.
Nathan A LackVancouver Prostate Centre, Vancouver, Canada.
David M PerrinDepartment of Chemistry, University of British Columbia, Vancouver, BC, Canada.
Michael E CoxDepartment of Urologic Sciences, University of British Columbia, 2775 Laurel Street, Vancouver, BC, V5Z 1M9, Canada.
S Larry GoldenbergDepartment of Urologic Sciences, University of British Columbia, 2775 Laurel Street, Vancouver, BC, V5Z 1M9, Canada. goldenb@me.com.
University of British Columbia · CAKoç University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate-specific membrane antigen (PSMA) is expressed in epithelial cells of the prostate gland and is strongly upregulated in prostatic adenocarcinoma, with elevated expression correlating with metastasis, progression, and androgen independence. Because of its specificity, PSMA is a major target of prostate cancer therapy; however, detectable levels of PSMA are also found in other tissues, especially in salivary glands and kidney, generating bystander damage of these tissues. Antibody target therapy has been used with relative success in reducing tumor growth and prostate specific antigen (PSA) levels. However, since antibodies are highly stable in plasma, they have prolonged time in circulation and accumulate in organs with an affinity for antibodies such as bone marrow. For that reason, a second generation of PSMA targeted therapeutic agents has been developed. Small molecules and minibodies have had promising clinical trial results, but concerns about their specificity had arisen with side effects due to accumulation in salivary glands and kidneys. Herein we study the specificity of small molecules and minibodies that are currently being clinically tested. We observed a high affinity of these molecules for PSMA in prostate, kidney and salivary gland, suggesting that their effect is not prostate specific. The search for specific prostate target agents must continue so as to optimally treat patients with prostate cancer, while minimizing deleterious effects in other PSMA expressing tissues.

Indexed as

Prostatic NeoplasmsAntigens, SurfaceHumansMaleProstate-Specific AntigenAntigens, SurfaceProstate-Specific AntigenFOHL1Prostate CancerPSMATargeted therapy

Identifiers

PMID37093434
OpenAlexW4366820616

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.